佛慈制药（002644）8月1日主力资金净流出2949.75万元

Core Insights - As of August 1, 2025, Foci Pharmaceutical (002644) closed at 10.43 yuan, down 1.42% with a turnover rate of 12.58% and a trading volume of 642,200 lots, amounting to 678 million yuan [1] - The latest quarterly report shows total revenue of 216 million yuan, a year-on-year decrease of 21.22%, while net profit attributable to shareholders was 19.38 million yuan, an increase of 5.41% [1] - The company has a current ratio of 3.630, a quick ratio of 2.665, and a debt-to-asset ratio of 24.19% [1] Financial Performance - Total revenue for Q1 2025 was 216 million yuan, down 21.22% year-on-year [1] - Net profit attributable to shareholders was 19.38 million yuan, up 5.41% year-on-year [1] - Non-recurring net profit was 14.35 million yuan, a slight decrease of 0.48% year-on-year [1] Capital Flow - Main capital outflow today was 29.50 million yuan, accounting for 4.35% of the total trading volume [1] - Large orders saw a net outflow of 12.98 million yuan, representing 1.92% of the trading volume [1] - Small orders experienced a net inflow of 12.20 million yuan, accounting for 1.80% of the trading volume [1] Company Overview - Foci Pharmaceutical Co., Ltd. was established in 2000 and is located in Lanzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 510.657 million yuan and a paid-in capital of 510.65 million yuan [2] - The legal representative of the company is Shan Xiaodong [2] Investment and Intellectual Property - The company has invested in 14 enterprises and participated in 2,083 bidding projects [2] - Foci Pharmaceutical holds 74 trademark registrations and 102 patents [2] - The company possesses 1,180 administrative licenses [2]